Alberto Garaventa

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

Susan L. Cohn, Andrew D.J. Pearson, Wendy B. London et al. · Journal of Clinical Oncology · 2008 · 1.9K citations

Medicine, Oncology, Pediatrics +14

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 401 citations

Life Sciences, Immunology, Oncology +8

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 348 citations · Full text

Medicine, Oncology, Pharmacology +8

Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.

Alberto Garaventa, Roberto Luksch, M. S. Lo Piccolo et al. · PubMed · 2003 · 189 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

European Intergroup Studies (MMT4-89 and MMT4-91) on Childhood Metastatic Rhabdomyosarcoma: Final Results and Analysis of Prognostic Factors

Modesto Carli, Raffaella Colombatti, Odile Oberlin et al. · Journal of Clinical Oncology · 2004 · 179 citations

Medicine, Oncology, Surgery +17